- Diseases
- Acoustic Neuroma (16)
- Adrenal Gland Tumor (24)
- Anal Cancer (70)
- Anemia (2)
- Appendix Cancer (18)
- Bile Duct Cancer (26)
- Bladder Cancer (74)
- Brain Metastases (28)
- Brain Tumor (234)
- Breast Cancer (726)
- Breast Implant-Associated Anaplastic Large Cell Lymphoma (2)
- Cancer of Unknown Primary (4)
- Carcinoid Tumor (8)
- Cervical Cancer (164)
- Colon Cancer (168)
- Colorectal Cancer (118)
- Endocrine Tumor (4)
- Esophageal Cancer (44)
- Eye Cancer (36)
- Fallopian Tube Cancer (8)
- Germ Cell Tumor (4)
- Gestational Trophoblastic Disease (2)
- Head and Neck Cancer (14)
- Kidney Cancer (130)
- Leukemia (342)
- Liver Cancer (50)
- Lung Cancer (286)
- Lymphoma (278)
- Mesothelioma (14)
- Metastasis (30)
- Multiple Myeloma (100)
- Myelodysplastic Syndrome (60)
- Myeloproliferative Neoplasm (6)
- Neuroendocrine Tumors (16)
- Oral Cancer (102)
- Ovarian Cancer (178)
- Pancreatic Cancer (160)
- Parathyroid Disease (2)
- Penile Cancer (14)
- Pituitary Tumor (6)
- Prostate Cancer (150)
- Rectal Cancer (58)
- Renal Medullary Carcinoma (6)
- Salivary Gland Cancer (14)
- Sarcoma (238)
- Skin Cancer (300)
- Skull Base Tumors (56)
- Spinal Tumor (12)
- Stomach Cancer (66)
- Testicular Cancer (28)
- Throat Cancer (92)
- Thymoma (6)
- Thyroid Cancer (100)
- Tonsil Cancer (30)
- Uterine Cancer (86)
- Vaginal Cancer (18)
- Vulvar Cancer (22)
- Cancer Topic
- Adolescent and Young Adult Cancer Issues (22)
- Advance Care Planning (12)
- Biostatistics (2)
- Blood Donation (18)
- Bone Health (8)
- COVID-19 (360)
- Cancer Recurrence (120)
- Childhood Cancer Issues (120)
- Clinical Trials (628)
- Complementary Integrative Medicine (22)
- Cytogenetics (2)
- DNA Methylation (4)
- Diagnosis (238)
- Epigenetics (6)
- Fertility (62)
- Follow-up Guidelines (2)
- Health Disparities (14)
- Hereditary Cancer Syndromes (128)
- Immunology (18)
- Li-Fraumeni Syndrome (8)
- Mental Health (122)
- Molecular Diagnostics (8)
- Pain Management (62)
- Palliative Care (8)
- Pathology (10)
- Physical Therapy (18)
- Pregnancy (18)
- Prevention (936)
- Research (390)
- Second Opinion (78)
- Sexuality (16)
- Side Effects (616)
- Sleep Disorders (10)
- Stem Cell Transplantation Cellular Therapy (216)
- Support (408)
- Survivorship (328)
- Symptoms (182)
- Treatment (1788)
Checkpoint blockade immunotherapy may potentially treat triple negative breast cancer
BY Ron Gilmore
2 minute read | Published February 15, 2018
Medically Reviewed | Last reviewed by an MD Anderson Cancer Center medical professional on February 15, 2018

Triple-negative breast cancer (TNBC), a highly aggressive, relapse-prone disease that accounts for one-fourth of all breast cancers, could potentially be treated with immune checkpoint blockade therapy.
Already used to treat other cancers, immune checkpoint blockade therapy relies on connections between PD-L1 and its sister molecule, PD1, found on T-cell surfaces, allowing cancer cells to go undetected by the immune system. Blocking PD-L1 and PD-1 interaction has been the basis for successful immunotherapies already in use in other cancers.
A team of MD Anderson researchers has found that in TNBC, a cell process called glycosylation is required for PD-L1/PD1 molecules to interact and identified exactly how and why glycosylation is so crucial.
“Glycosylation is a process that attaches portions of sugar molecules called moieties to the protein providing it fuel to grow and spread,” said Mien-Chie Hung, Ph.D., chair of Molecular and Cellular Oncology. “Glycosylation of PD-L1 in tumor cells stabilizes PD-L1, but it is largely unknown whether sugar moiety by itself is required for binding to PD-1 to suppress anti-tumor immunity.”
Hung’s research group shed further light in this area through discovery of glycosylated PD-L1 (gPD-L1), and worked with STCube Pharmaceuticals Inc. to develop anti-gPD-L1 antibodies that recognize this glycosylated form of PD-L1, killing tumor cells while not harming healthy ones.
To improve the therapeutic efficacy of anti-gPD-l1 antibody, the team linked a potent small molecule chemotherapy agent, called MMAE, to the anti-gPD-L1, creating a new antibody drug conjugate (ADC), called anti-gPD-L1-MMAE, which resulted in higher therapeutic efficacy in animal models. Hung believes the development of this glycosylated PD-L1 ADC (anti-gPD-L1-MMAE) may represent a new generation of immunotherapy that is more targeted with fewer adverse effects.
“We demonstrated that gPD-L1 is an excellent candidate for ADC as sugar moiety is critical for PD-L1’s detrimental role in TNBC,” said Hung. “Immune checkpoint blockade treatment options remain limited in TNBC, so identifying new immune checkpoint targets to improve upon current therapy is urgently needed.”